secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2023-05-02T23:59:59+00:00
Accession:  0000950170-23-016684
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion reports Q1 net loss $29.1M, cash $86.7M plus $172.5M offering; positive Phase II diabetes data
--------------------------------------------------------------------------------

- Net loss $29.1M vs $16.4M in Q1 2022; R&D expense $24.4M (up from $11.4M).
- Cash $86.7M at Mar 31, 2023; plus $172.5M gross from April offering to ≈$259M total.
- COVALENT-111 Phase II Cohort 3 (100 mg): 89% of patients had HbA1c reduction, 56% had ≥1% reduction.
- IND cleared for BMF-500; Phase I COVALENT-103 for FLT3-mutant acute leukemias to start enrolling.
- Initial AML/ALL data from COVALENT-101 expected in Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000095017023016684/0000950170-23-016684-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000095017023016684/bmea-20230502.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-016684

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer